Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
ER

NASDAQ · ERAS

Erasca, Inc.

Healthcare · Biotechnology

$14.35

Down-$0.63 (-4.21%)

Updated Nov 2, 2026, 7:12 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
958.95M
P/E ratio
-7.47
Dividend yield
0.00%
52-week range
$2.11 – $24.28
Volume
3.75M
Avg. volume
1.84M

Price performance · ERAS

ERAS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ERAS closed at $14.35 after 20 trading sessions, down 2.51% for the selected period.

Last close
$14.35
Period change
-2.51%
Period low
$13.39
Period high
$16.03
Daily close
View OHLC price history
ERAS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$14.66$15.01$14.035$14.353.75M
Oct 29, 2026$15.11$15.45$14.66$14.982.28M
Oct 28, 2026$14.90$15.32$14.45$15.123.41M
Oct 27, 2026$14.95$15.26$14.72$15.225.83M
Oct 26, 2026$14.58$15.47$14.545$14.996.47M
Oct 23, 2026$13.99$14.445$13.44$14.393.5M
Oct 22, 2026$14.22$14.645$13.815$14.042.3M
Oct 21, 2026$14.82$15.05$14.38$14.493.85M
Oct 20, 2026$13.40$14.97$13.10$14.624.22M
Oct 19, 2026$13.73$13.98$13.34$13.624.26M
Oct 16, 2026$14.87$14.87$13.265$13.397.09M
Oct 15, 2026$14.71$15.26$14.36$14.878.48M
Oct 14, 2026$14.41$15.08$14.29$14.704.75M
Oct 13, 2026$15.25$15.5799$14.50$14.785.31M
Oct 12, 2026$15.885$16.01$15.32$15.464.28M
Oct 9, 2026$15.42$16.20$15.215$16.037.77M
Oct 8, 2026$13.96$15.62$13.7802$15.469.61M
Oct 7, 2026$14.09$14.57$13.93$14.123.85M
Oct 6, 2026$14.74$14.93$14.02$14.308.04M
Oct 5, 2026$14.74$15.03$13.8034$14.725.49M

Latest ERAS news

The latest Smart Investors Daily articles mentioning ERAS.

Stock researchCompany · Overview

ERAS research

Overview

Company profile and research snapshot.

Company profile

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$5.50
Implied upside
—
Analysts
16
ERAS recent ratings
DateFirmRatingTarget
Aug 14, 2026B of A SecuritiesNeutral—
Aug 13, 2026GuggenheimBuy—
Aug 12, 2026HC Wainwright & Co.Buy—
Jul 20, 2026Morgan StanleyEqual-Weight—
Jul 14, 2026B of A SecuritiesNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Erasca (ERAS), What Is Driving Attention Around The Stock Today?

The real story around Erasca (ERAS) right now is not a trial readout or financing. It is a legal probe into how management described key risks around its pan RAS candidate ERAS-0015. Erasca’s share price has been volatile around this scrutiny. The stock closed at US$14.99, with a 1-day share price return of 4.17% and a 7-day gain of 10.06%. However, the 90-day move shows a decline of 17.46% as enthusiasm cools from a very large 1-year total shareholder return of about 7x, which still dwarfs...

Yahoo · Oct 19, 2026

Erasca (ERAS) Stock Looks Above Fair Value After Its 5x Run

Erasca has delivered a very large share price gain over the past three years, which puts a spotlight on whether that move still lines up with what its balance sheet and book value can support. With the stock now well above its past lows and investors digesting legal and clinical headlines, the question is how firmly the current price rests on tangible net assets. Over the past 3 years the share price has climbed about 5x, which raises the issue of how much of that rise can be grounded in the...

SeekingAlpha · Oct 15, 2026

Erasca, Inc.: The Discount RevMed?

Erasca targets the KRAS inhibitor market with early cancer data, Fast Track status, and 2027 trials ahead. Click to read this latest analysis of ERAS stock.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By